Clinical Trial Update: Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Ixmyelocel-T for treating critical limb ischemia in peripheral arterial disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Arterial Disease

Drugs mentioned

• Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) (Ixmyelocel-T)

Snippet

Sponsor: Vericel Corporation | Conditions: Peripheral Arterial Disease | Phase 2 | Status: COMPLETED